Dankang BioHealth
Finnrick has tested 74 samples from Dankang BioHealth across 8 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| GHK-Cu | 6 | 19 Jan 2026 | 1 Jun 2026 | |||||
| Tesamorelin | 9 | 19 Jan 2026 | 27 May 2026 | |||||
| NAD+ | 5 | 22 Feb 2026 | 6 May 2026 | |||||
| BPC-157 | 4 | 7 Jan 2026 | 27 May 2026 | |||||
| MOTS-c | 5 | 4 Mar 2026 | 28 Apr 2026 | |||||
| Retatrutide | 31 | 1 Jan 2026 | 24 Jun 2026 | |||||
| TB-500 | 4 | 19 Jan 2026 | 1 Jun 2026 | |||||
| Tirzepatide | 10 | 22 Jan 2026 | 17 Jun 2026 | |||||
The Dankang BioHealth samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 75 overall satisfaction reports
People who submitted test requests to Finnrick gave Dankang BioHealth an average satisfaction rating of 4.8 out of 5 across 75 reports associated with samples received and tested by Finnrick.
Most recent Dankang BioHealth tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Variant | Test Score | Label | Batch | Tested | Difference | Purity | Endotoxins | Batch ID | Container | Tested At | Sent By |
| 24 Jun 2026 | Retatrutide | View | 10mg | (no batch claim) | 11.6mg | +16.0% | 99.90% | n/a | 2 | No label / Silver crimp / Black cap | Lab E | Public | ||
| 17 Jun 2026 | Tirzepatide | View | 5mg | ⚠️ Sample does not contain Tirzepatide | n/a | 2026/03 | No label / Silver crimp / White cap | Lab G | Public | |||||
| 17 Jun 2026 | Retatrutide | View | 5mg | ⚠️ Sample does not contain Retatrutide | n/a | 2026/3 | No label / Silver crimp / White cap | Lab G | Public | |||||
| 1 Jun 2026 | TB-500 | View | Thymosin Beta-4 | 10mg | (no batch claim) | 8.37mg | -16.3% | 99.60% | n/a | DK3707202602 | (no data) | Lab E | Public | |
| 1 Jun 2026 | GHK-Cu | View | 100mg | (no batch claim) | 86.6mg | -13.4% | 99.90% | below LOQ | (no batch ID) | White label / Silver crimp / White cap | Lab E | Public | ||
| 1 Jun 2026 | Retatrutide | View | 20mg | (no batch claim) | 18.8mg | -6.0% | 99.90% | below LOQ | (no batch ID) | White label / Copper crimp / Clear cap | Lab E | Public | ||
| 27 May 2026 | TB-500 | View | 10mg | ⚠️ Sample does not contain TB-500 | n/a | 2026/02 | No label / Silver crimp / White cap | Lab E | Public | |||||
About Dankang BioHealth Test Results From Finnrick
Dankang BioHealth is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 8 products and 74 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Dankang BioHealth Testing Activity & Score Summary
In the past 30 days, Finnrick has published 3 new test results for Dankang BioHealth, and 37 in the past three months. The overall dataset includes 74 tested samples with an average score of 6.1/10 across all products.
Across 74 identity-tested samples, 88% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 94% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (31 tests, 87% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 6.7/10), suggesting significant batch-to-batch differences.
- Tirzepatide (10 tests, 70% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 5.7/10), suggesting significant batch-to-batch differences.
- Tesamorelin (9 tests, 100% identity pass, median purity 99.7%) — Test scores are highly variable, ranging from 4.3 to 8.0 (average 6.2/10), suggesting significant batch-to-batch differences.